Comparison
Ipamorelin vs. SNAP-8
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Cosmetic
CAS no.
170851-70-4
868844-74-0
Molecular weight
711.86 g/mol
1075.16 g/mol
Half-life
2 h
no data
Sequence
Aib-His-D-2-Nal-D-Phe-Lys-NH2Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2Mechanism of action
Ipamorelin
Ipamorelin is a selective agonist at the GH secretagogue receptor (GHSR-1a). Compared to GHRP-2 and GHRP-6 its selectivity for the growth-hormone axis is higher; ACTH, cortisol and prolactin are not significantly stimulated in clinical studies. This selectivity was the main reason for its development over older GHRPs.
SNAP-8
SNAP-8 is an octapeptide variant of Argireline. The sequence corresponds to the N-terminus of the SNAP-25 protein. As with Argireline, the postulated mechanism is competitive inhibition of the SNARE complex needed for acetylcholine vesicle fusion at the neuromuscular endplate. According to the manufacturer the two extra C-terminal amino acids increase SNARE-complex affinity — there are individual industry studies on this but no independent systematic confirmation.
Evidence base
Highest evidence
Human RCT
Human trial
Studies
4
3
of which in humans
3
1
Effects recorded
3
3
Open conflicts
1
0
Documented adverse events
1
1